Copy Link Print Information

Luspatercept

(Synonyms: ACE-536; luspatercept–aamt)
5 Cited Publications
Avis client

Based on 5 publication(s) in Google Scholar

Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • Pureté: 98.92%
  • CAS No.: 1373715-00-4
  • Masse moléculaire:75.71 kDa
  • Stockage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Luspatercept
  • Experimental Validation Results for Luspatercept
  • Experimental Validation Results for Luspatercept
  • Experimental Validation Results for Luspatercept
  • Experimental Validation Results for Luspatercept
  • Experimental Validation Results for Luspatercept
  • Experimental Validation Results for Luspatercept
  • Experimental Validation Results for Luspatercept
  • Experimental Validation Results for Luspatercept
  • Experimental Validation Results for Luspatercept
  • Experimental Validation Results for Luspatercept
  • Experimental Validation Results for Luspatercept
  • Luspatercept Chemical Structure
    Luspatercept Chemical Structure
CAS No.: 1373715-00-4
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or

* Veuillez sélectionner la quantité avant d'ajouter des articles.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Luspatercept:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Trouvez votre distributeur local Your local distributor: Hycultec GmbHHycultec
  • Activité biologique
  • Chemical Information
  • Pureté et documentation
  • Références
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Luspatercept

More
Customer Validation & Images
In Vivo Efficacy StudyBio/Physico-chemical AssayCell Imaging/StainingRT-PCRWBIF
  • Bio/Physico-chemical Assay
  • Cell Imaging/Staining
  • RT-PCR
  • WB
  • IF
  • In Vivo Efficacy Study
  • In Vivo Efficacy Study

Voir tous les produits spécifiques à Isoform TGF-beta/Smad

More
Keywords
MOQ
Minimum order quantity
100 mg

Obtenir un devis En stock

Other size
Obtenir un devis
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Enregistrer
Sign in to MedChemExpress
Enregistrer un nouveau compte

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    [ACVR2B (activin A receptor type 2B, ActR-IIB, ActRIIB)]2-IGHG1 Fc (Fragment constant)

  • 1/16

    Immobilized HY-P72632 GDF-8 Protein, Human/Mouse/Rat (HEK293) can bind Luspatercept. The EC50 for this effect is 74.63 ng/mL.

  • 1/16

    Immobilized HY-P70222Y GDF-11/BMP-11 Protein, Human (HEK293, solution) can bind Luspatercept. The EC50 for this effect is 99.57 ng/mL.

  • 1/16

    Immobilized Recombinant Anti-ACVR2B Antibody can bind Luspatercept. The EC50 for this effect is 3.08 ng/mL.

  • 1/16

    Loaded Luspatercept on CM5 biosensor, GDF-11/BMP-11 Protein, Human (HEK293, HY-P70222Y) with an affinity constant of 1.80E-08 M as determined in SPR assay.

  • 1/16

    Luspatercept purchased from MedChemExpress. Usage Cited in: Blood Adv. 2025 Nov 5:bloodadvances.2025017340. [Abstract]

    Customer Validation
     Percentages of benzidine-positive K562 cells (blue) treated with 1 μg/mL luspatercept for 0 to 3 days, compared with nontreated control (NTC) cells (n = 3). One-way ANOVA was used for statistical analysis.

  • 1/16

    Luspatercept purchased from MedChemExpress. Usage Cited in: Blood Adv. 2025 Nov 5:bloodadvances.2025017340. [Abstract]

    Customer Validation
     Representative images of benzidine staining of K562 cells treated with 1 μg/mL luspatercept for 0 to 3 days. The red arrows indicate benzidine-positive cells (blue). The images are representative of 3 independent experiments.

  • 1/16

    Luspatercept purchased from MedChemExpress. Usage Cited in: Blood Adv. 2025 Nov 5:bloodadvances.2025017340. [Abstract]

    Customer Validation
     Relative mRNA levels of UBE2O and GATA1 in K562 cells on days 0 to 3 after treatment with 1 μg/mL luspatercept on day 0. One-way ANOVA was used for statistical analysis (n = 3).

  • 1/16

    Luspatercept purchased from MedChemExpress. Usage Cited in: Blood Adv. 2025 Nov 5:bloodadvances.2025017340. [Abstract]

    Customer Validation
     Representative western blot analysis of UBE2O, GATA1, and p-Smad3 in K562 cells treated with 1 μg/mL luspatercept for 0 to 3 days. Vinculin and GAPDH were used as loading controls.

  • 1/16

    Luspatercept purchased from MedChemExpress. Usage Cited in: Blood Adv. 2025 Nov 5:bloodadvances.2025017340. [Abstract]

    Customer Validation
     Representative images of immunofluorescence staining for UBE2O in K562 cells treated with 1 μg/mL luspatercept for 0 to 2 days, compared with NTC cells (n = 5). DAPI staining was used to highlight nuclei.

  • 1/16

    Luspatercept purchased from MedChemExpress. Usage Cited in: Science. 2024 Nov 15;386(6723):eadh9215. [Abstract]

    Customer Validation
     Treatment of β-thalassemic mice with Luspatercept (10 mg/kg twice every week for 8 weeks), an activin receptor IIB ligand trap that promotes late-stage erythropoiesis, led to decreased frequencies of erythroid precursors (ProE and BasoE) and increased levels of RBCs, HCT and Hgb.

  • 1/16

    Luspatercept purchased from MedChemExpress. Usage Cited in: Science. 2024 Nov 15;386(6723):eadh9215. [Abstract]

    Customer Validation
     Luspatercept (10 mg/kg twice every week for 8 weeks) treatment decreased the abundance of glutamate and increased glutamine-to-glutamate ratios in mouse β-thalassemic erythroid cells.

  • Luspatercept Chemical Structure
    1/16
  • Luspatercept
  • Immobilized HY-P72632 GDF-8 Protein, Human/Mouse/Rat (HEK293) can bind Luspatercept. The EC50 for this effect is 74.63 ng/mL.
  • Immobilized HY-P70222Y GDF-11/BMP-11 Protein, Human (HEK293, solution) can bind Luspatercept. The EC50 for this effect is 99.57 ng/mL.
  • Immobilized Recombinant Anti-ACVR2B Antibody can bind Luspatercept. The EC50 for this effect is 3.08 ng/mL.
  • Loaded Luspatercept on CM5 biosensor, GDF-11/BMP-11 Protein, Human (HEK293, HY-P70222Y) with an affinity constant of 1.80E-08 M as determined in SPR assay.